Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-05
1999-11-16
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 514 62, 536 53, 536 552, 536 88, 5361231, A61K 3170
Patent
active
059858508
ABSTRACT:
A dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of an agent to treat a disease or condition involving underperfused tissue and pathological tissue in humans and a form of hyaluronic acid, wherein the form of hyaluronic acid is available to transport the agent from the point of administration to the site to be treated.
REFERENCES:
patent: 2583096 (1952-01-01), Hididian et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4272522 (1981-06-01), Balazs
patent: 4303676 (1981-12-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4900550 (1990-02-01), Loury
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4946870 (1990-08-01), Partian, III et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5166331 (1992-11-01), della Valle et al.
patent: 5181276 (1993-01-01), Kersten et al.
Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of the Globe and Mail, Toronto, Ontario, p. D4.
Pam Harrison, "Toxic drug tamed but still potent" Ontario Medicine, vol. 8, No. 16 dated Aug. 21, 1989, p. 1.
The Merck Index Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751 and 752.
Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II (will follow).
Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York, (1981) (will follow).
Dr. Samuel Asculai, "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", Antimicrobial Agents and Chemotherapy, Apr. 1978, pp. 686-690. (will follow).
Alaverdyn MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. vol. III. New York: Academic Press, 1970. pp. 1241-1253.
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784.
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B.
Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); vol. 111: 520-521.
Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446.
Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 384-388.
Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (1973 Jan.-Feb.); 16 (1): 84-88.
Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68.
Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 736-738.
Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon.RTM.). Z. Rheumatol (1982); 41: 202-211.
Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. Nippon Rinsho (Jan. 1968); 26(1): 89-95.
Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. Transplantation (Feb. 1984); 37(2): 139-145.
McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medical Association 1982; Feb. 1: 239-250.
Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. Nippon Rinsho (Jan. 1986); 26(1): 61-65.
Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. The Cornell Veterinarian 1981; 71(4): 355-375.
Pigman W, et al. Acide hyaluronique et facteurs de permeabilite tissulaire. Bull. Soc. Chim. Biol. 1963; 5(2-3): 185-202.
Pruett RC, Schepens CL, Constable IJ, Swann DA. Hyaluronic acid vitreous substitute. In: Vetreous Surgery and Advances in Fundus Diagnosis and Treatment. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55 pp. 433-444.
Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.
Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 1971; 80(Oct.): 25-29.
Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extrative mucopolysaccharide complex. Current Therapeutic Research 1978; 23(4): 455-463.
Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Acta Ophthalmol. 1986; 18: 9-13.
Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severly obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. Pharmatherapeutica 1988; 5(4): 233-239.
Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofo-circolatorie degli arti inferiori. (Comunicazioni). Giornale Italiano di Dermatologia 1970; 45(8): 468-471.
Walther, M. The Prevention of Strine Cutis Distansae During Pregnancy. Mineva Gynecolgia (1981) vol. 33: 497-499.
Weirich, E.G., Longauer, J.K., Kirkwood, A.H. Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of salicylic acid and other durgs in animal experiments. Dermatologica (1976); 152(2): 87-99.
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. vol. III. New York: Academic Press, 1970. pp. 1241-1253.
Balazs EA, Band P. IIyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985;
Asculai Samuel S.
Falk Rudolf Edgar
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceuticals Corporation
Peselev Elli
Sarkis Marcelo K.
LandOfFree
Compositions comprising hyaluronic acid and drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising hyaluronic acid and drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising hyaluronic acid and drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1324851